03:16pm Sunday 15 December 2019

Anti-epileptics: tough choices during pregnancy

The authors of the study say evidence on the safety of anti-epileptic drugs is limited and that more research is needed to ensure women and their doctors make the best choices.

Studies on animals and children born to women with epilepsy increasingly suggest that some anti-epileptic medications affect development in the womb. However, most women with epilepsy rely on these medications to control seizures during pregnancy.

To assess the safety of taking anti-epileptics during pregnancy, the researchers drew together evidence from 28 studies. They measured children’s global cognitive ability using either intelligence quotient (IQ), for school-aged children, or developmental quotient (DQ), for younger children, to provide a summary of development across a range of cognitive skills. The researchers looked at DQ and IQ scores in the children of three groups of women: those with epilepsy who took anti-epilepsy medication, those with epilepsy who did not take epilepsy medication and those without epilepsy.

The children of women who took one drug, sodium valproate, had lower DQs and IQs than the children of women in the other groups. Higher doses of this drug were linked to larger effects on IQ or DQ. However another drug, carbamazepine, did not appear to have any significant effects on DQ or IQ.

Younger children born to women who took carbamazepine did have lower DQs but the researchers concluded this was due to random variation between studies.

“This review highlights the need for preconception counselling in women with epilepsy,” said Dr Rebecca Bromley, lead researcher of the study based at the Institute of Human Development at The University of Manchester. “Counselling should take account of the fact that many pregnancies are unplanned and cover the risks of anti-epileptic drugs, whilst considering how well they control epileptic seizures.”

Some studies made comparisons between different drugs. The children of women who took valproate had lower IQs than those of women who took carbamazepine or lamotrigine, and lower DQs and IQs than those of women who took phenytoin. There were no differences between the IQs of children exposed to either carbamazepine, phenytoin or lamotrigine.

Only a few studies analysed the effects of newer anti-epileptic drugs like lamotrigine, levetiracetam and topiramate. “Data was not available for all anti-epileptic drugs that are in use today and data on newer anti-epileptic drugs was especially scarce,” said Dr Bromley. “This makes it difficult for women and their doctors to know which medications are safe to use during childbearing years. Future research needs to be carried out in a timelier manner to ensure that when prescribing decisions are being made the risks are already established.

“Women should, however, not stop or make alterations to their medication without first seeking medical advice.”

Cochrane is an independent, trusted producer of research into the effects of healthcare treatments and interventions. Policy makers, health practitioners and patients can make better decisions using accessible, high quality, trusted evidence.


Notes for editors


Funding: Aspects of this work were supported by the National Institute for Health Research (NIHR) (project numbers 10/4001/18 and PDF-2016-06-041).

Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.

Full citation:

Bromley R, Weston J, Adab N, Greenhalgh J, Sanniti A, McKay AJ, Tudur Smith C, Marson AG. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews 2014, Issue 10. Art. No.: CD010236. DOI: 10.1002/14651858.CD010236.pub2.

For media enquiries, please contact Jamie Brown | Media Relations Officer | The University of Manchester | +44(0)161 275 8383 | Jamie.brown@manchester.ac.uk |

Share on:

MORE FROM Pregnancy and Childbirth

Health news